Schrodinger Inc

SDGR

Equity

ISIN US80810D1037 / Valor 51947209

NASDAQ (2024-11-21)

USD 20.37+6.26%

Schrodinger Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Schrodinger Inc is a company that focuses on reducing risk in drug discovery and development by selecting high-value targets with established human genetics or clinical validation. The company aims to solve design challenges and deliver value for patients through its therapeutics group. With a strong emphasis on innovation and scientific expertise, Schrodinger Inc plays a crucial role in advancing the field of pharmaceutical research and development.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Schrodinger Inc's total revenue for the full year 2023 increased by 19.7% to $216.7 million, compared to $181.0 million in 2022. This growth was significantly driven by multi-year agreements and larger renewals of annual contracts among existing customers.

Drug Discovery Revenue

For the full year 2023, Schrodinger Inc reported drug discovery revenue of $57.5 million, a notable increase from $45.4 million in 2022. This segment's growth highlights the company's expanding footprint in the drug discovery market.

Software Gross Margin

Schrodinger Inc achieved a software gross margin of 81% for the full year 2023, up from 78% in 2022. This improvement reflects the company's efficient cost management and increased profitability in its software segment.

Net Income

Schrodinger Inc reported a net income of $40.7 million for the full year 2023, a significant turnaround from a net loss of $149.2 million in 2022. This positive shift was influenced by substantial gains in other income, including equity investments and interest income.

Cash Position

As of December 31, 2023, Schrodinger Inc had cash, cash equivalents, restricted cash, and marketable securities totaling approximately $468.8 million. This compares to $456.3 million at the end of 2022, indicating a stable cash position despite fluctuations during the year.

Summarized from source with an LLMView Source

Key figures

-30.5%1Y

-50.1%3Y

%5Y

Performance

60.3%1Y

66.4%3Y

72.2%5Y

Volatility